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the ASSURE project. In this preliminary analysis, the comparative cost-effective-
ness of personalised screening strategies and current practice was calculated as 
a cost-per-case-detected from a health service perspective. Uncertainty in the 
cost-effectiveness estimate is investigated using one-way sensitivity analyses 
of key parameters. Results: The incremental cost-effectiveness ratio of a three 
risk group stratification procedure in the base case was £45,617 per-case-detected. 
Influential parameters were sensitivity of mammography, recall rate, cancer 
growth parameters and accuracy of risk estimation. ConClusions: A very simple 
stratification procedure may not be cost-effective. The optimal risk stratification 
for personalised breast screening will be investigated to determine whether this 
offers improvement in cost-effectiveness.
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objeCtives: Besides being associated with a negative impact on patients’ lives 
and a low 5-year survival rate[1], stage IV (metastatic) breast cancer is accompa-
nied with high treatment costs. The objective of this research was to analyse recent 
HTA decisions on metastatic breast cancer of different national HTA bodies world-
wide and investigate reasons for variances in their decision making. Methods: 
Reimbursement decisions for metastatic breast cancer treatments across various 
national HTA bodies published between January 2013 and May 2015 were analysed. 
Factors such as variations in treatment guidelines, different disease mutations, 
specific lines of therapy or if the drug was a single or add-on treatment were not 
considered. Each HTA decision was analysed according to the following criteria: 
clinical value, survival benefit, price, ICER (where applicable), toxicity and quality 
of life. Treatments were not compared with each other, but the HTA evaluation of 
each treatment was considered across the single countries. Results: A review of 5 
breast cancer medications recently assessed independently across 9 HTA authori-
ties (6 European HTA bodies, Canada, Australia, Japan) showed that generally, 
drugs with sufficient proof of clinical value were nationally reimbursed. Positive 
reimbursement decisions for all treatments were made in Germany and France, 
while NICE and SMC only gave negative opinions. Most common reasons for non-
approvals or restrictions were “lack of cost effectiveness” and “lack of clinical 
value” in respectively 10 and 3 of the HTA submissions. ConClusions: HTA deci-
sions for metastatic breast cancer treatments differ across countries, with some 
appearing to be more willing to reimburse medications. Clinical effectiveness was 
the most important decision factor for 5 countries, whereas cost-effectiveness 
was more relevant to the remaining 4 HTA bodies. With novel medications for 
metastatic breast cancer coming to market in the next years[2], certain criteria for 
HTA assessments might need to be re-defined. [1] http://www.cancer.org/cancer/
breastcancer/detailedguide/breast-cancer-survival-by-stage [2] http://ww5.komen.
org/BreastCancer/EmergingMetasticBreastCancer.html
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objeCtives: Payers are seeking improvements in outcomes that are meaningful 
for the patient, but the preference of payers on what change can be considered 
meaningful is not well defined. Clinically relevant differences (CRDs) in outcomes 
and grading of their magnitude in oncology are being established by both European 
and American oncology organisations (European Society for Medical Oncology 
(ESMO) and American Society of Clinical Oncology (ASCO)). This indicates a transi-
tion from a focus primarily on statistical significant improvements (i.e., “is there 
a difference?”) in outcomes towards the clinical relevance of these improvements 
(i.e., “does the difference matter to patients?”). The attitude of payers towards 
CRDs in oncology outcomes is not well-understood, with little guidance around 
oncology CRDs from payers. The objective of this study is to evaluate the align-
ment between payers and clinicians in their assessment of clinical and health 
benefit of oncology products. Methods: Oncology products launched recently 
were evaluated using the approach suggested by ESMO and ASCO. For the same 
products, the payer decision was evaluated to establish the clinical and health 
benefit rating by NICE (UK), HAS (France) and G-BA (Germany). Results: Not all 
products granted market approval have been evaluated by payers. The research 
showed that where they had been evaluated, payer quantification of clinical ben-
efit differed to that recommended by oncology societies. Furthermore, clinical 
benefit assessment, particularly regarding overall survival improvement, differed 
between payers themselves. ConClusions: Oncology societies are recognising 
the need to ensure consistent assessment and representation of clinical benefit 
of new oncology products. Whilst payers often have guidance on how they assess 
benefit, this is often generic and applied across therapy areas. As a consequence, 
there still remains an inconsistent approach to evaluating clinical benefits in 
oncology between payers, which provides challenges and implications in drug 
development programmes for novel oncology therapies.
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objeCtives: Cancer is the most common cause of mortality in England and Wales. 
This study investigated whether the number of technologies assessed by NICE for 
a specific cancer reflects its prevalence in England and Wales Methods: 1-year 
elements more important to assessing value may improve these processes and 
contribute to giving a fairer access to appropriate treatments to patients.
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objeCtives: The end-of-life consideration introduced by NICE in January 2009 allows 
extension of the upper limit of the cost-effectiveness thresholds beyond £30,000 per 
QALY for therapies that are indicated in patients with a short life expectancy and for 
small patient populations, with survival benefit of at least 3 months. The aim of this 
study was to assess the impact of the end-of-life considerations on health technol-
ogy assessment (HTA) recommendations for oncology therapies. Methods: NICE 
single technology appraisals (STAs) for oncology therapies published between 2009 
and June 11, 2015 were assessed. End-of-life consideration, HTA recommendations, 
incremental cost-effectiveness ratio (ICER) values and the availability of patient access 
schemes were extracted. Results: A total of 53 STAs were identified during the study 
period and 20 appraisals/therapies met the end-of-life criteria. Maximum end-of-life 
considerations were granted in the year 2009 and 2012 (4 each), while 2013 to 2015 
recorded the minimum (2 each). Of the therapies meeting the end-of-life criteria, 13 
received positive recommendations with the ICER values ranging from £31,800 to 
£58,590. Highest percentage of positive recommendations were reported in the year 
2009 (100%), whereas no positive recommendations were recorded in 2013, which 
could be attributable to the high ICER values of the end-of-life therapies appraised in 
2013 (£40,000 to £100,000). In 2014 and 2015 each, 50% therapies (1/2) received positive 
recommendations. Of the 13 positive recommendations, 11 included patient access 
schemes by manufacturers. Unacceptably high ICER values followed by economic 
modelling issues leading to uncertain ICER values were major drivers of negative deci-
sions. ConClusions: The use of end-of-life criteria for maximizing patient access 
remains suboptimal, as fewer treatments have met the end-of-life criteria in recent 
years. Also, increasing ICER values in end-of-life cancer appraisals have resulted in 
negative decisions. Patient access schemes by manufacturers may improve patients’ 
access to novel end-of-life oncology therapies.
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objeCtives: A key challenge for successful introduction of new drugs in meta-
static breast cancer (MBC) is a positive health technology assessment (HTA) 
outcome across Europe. Thus, understanding of the MBC HTA landscape is essen-
tial. This study aims to identify key decision drivers and challenges for HTA in 
MBC. Methods: An in-depth analysis of published HTA submissions in MBC over 
the last 5 years was conducted. In total, 96 HTA reports in MBC from 9 agencies 
were identified. Based on submission type and approval status, 38 HTA assess-
ments for 8 drugs were selected for further analysis. The analysis focussed on the 
submitted data and valuation by the different agencies. Outcomes were validated 
in an HTA expert meeting. Results: Of 38 HTA assessments, 11 received a nega-
tive recommendation, 8 a positive recommendation, and 13 a positive recom-
mendation with restrictions. The remaining 6 assessments were ongoing/did not 
provide a recommendation as yet. The majority of submissions included RCTs 
with PFS as primary endpoint and OS as secondary endpoint. HRQoL was not 
provided in 13/38 cases, with criticism in 8/38 cases. Some criticism was expressed 
regarding the logistics of HRQoL collection. The weight assigned to significance 
and incremental PFS and OS differed between countries. Twenty-eight of 38 sub-
missions included a PE evaluation. The key uncertainties in economic modelling 
related to validation of OS and PFS modelling (9/28) and the incorporation of 
safety data (11/28). Unfavourable ICERs and uncertainty in economic modelling 
were key drivers for negative decisions. ConClusions: Gaining favourable HTA 
recommendation for new MBC drugs is challenging. In order to improve probability 
of successful introduction of a new MBC drug, demonstrating significant and clini-
cally meaningful incremental OS and/or PFS is key, as is providing strong HRQoL 
data. Moreover, well-validated PE model and acceptable ICERs are important to 
gain favourable HTA opinion.
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objeCtives: This study estimates the cost-effectiveness of personalised breast 
cancer screening compared to one-size-fits-all screening. Personalised breast 
cancer screening has been proposed to both improve outcomes and screening 
programme efficiency. In a personalised screening programme frequency of 
mammography is varied based on women’s estimated risk of breast cancer. The 
Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation 
(ASSURE) project is a Europe-wide programme of work investigating new tech-
nologies and strategies in personalised screening. As there is substantial uncer-
tainty at this stage about several aspects of personalised screening the objective 
of this study is to provide information on which parameters are key in determin-
ing whether or not this strategy is cost-effective. Methods: The structure of an 
economic model to assess the cost-effectiveness of personalised screening was 
developed with input from clinical experts. A preliminary proposal uses three risk 
groups with triannual, biannual and annual screening offered. The modelling tech-
nique of discrete event simulation was used to combine a natural history model 
of breast cancer, risk stratification procedures, screening processes and expected 
outcomes over a lifetime horizon. Parameters in this mathematical model were 
informed by previously published modelling studies and data gathered within 
